|
|
| Line 1: |
Line 1: |
| __NOTOC__
| |
| {{Interferon alfa-2a}}
| |
| {{CMG}}
| |
|
| |
|
| ==Microbiology==
| |
|
| |
| ===Antiviral Activity in Cell Culture===
| |
|
| |
| In the stable [[HCV]] cell culture model system ([[HCV]] replicon), [[ribavirin]] inhibited autonomous [[HCV]] RNA replication with an effective concentration (EC50) value of 11-21 mcm. In the same model, PEG-IFN α-2a also inhibited [[HCV]] RNA replication, with an EC50 value of 0.1-3 ng/mL. The combination of PEG-IFN α-2a and [[ribavirin]] was more effective at inhibiting [[HCV]] RNA replication than either agent alone.
| |
|
| |
| ===Resistance===
| |
|
| |
| Different [[HCV]] genotypes display considerable clinical variability in their response to PEG-IFN-α and [[ribavirin]] therapy. Viral genetic determinants associated with the variable response have not been definitively identified.
| |
|
| |
| ===Cross-resistance===
| |
|
| |
| Cross-resistance between IFN-α and [[ribavirin]] has not been observed.<ref>{{Cite web | last = | first =|title = http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf| url =http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103964s5204lbl.pdf | publisher = |date = | accessdate = }}</ref>
| |
|
| |
| ==References==
| |
| {{Reflist}}
| |
|
| |
| {{FDA}}
| |
|
| |
| [[Category:Antiviral]]
| |
| [[Category:Wikinfect]]
| |